Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Iran plans new restrictions in overhaul of Strait of Hormuz rules - 2NASA astronauts to return from space early due to an 'unexpected medical issue.' What happened — and when are they coming home?
- 3Why Tourists May Want To Reconsider Traveling To This Popular Spot In Italy In 2026
- 4Palestinian leader Abbas says elections only after Gaza war ends
- 57 Heavenly Espressos, One Do You Like?
- Everyday Seasonal Positions That Compensate Fairly in the US
- The most effective method to Move toward Compensation Conversations for Cutting edge Practice Enrolled Attendants
- Become the best at Discussion: 6 Procedures for Progress
- Best Pizza Beating: What's Your #1?
- IDF says up to 90% of Iran’s weapons industry could be hit within days
- 'Heated Rivalry's Ilya Rozanov is now a queer icon in Russia
- Ways to track down the Right Criminal Legal counselor
- Virtual reality opens doors for older people to build closer connections in real life
- Must-See Attractions in Washington, D.C.
